UNITY single-sample prenatal screening

The real edge is workflow, not just science. Most prenatal screens from incumbents are built to flag chromosome level problems like trisomies from a maternal blood draw, then route single gene risk through a separate carrier screening path that often needs the father’s sample. UNITY collapses that extra step, so an OB can order one blood draw, get maternal carrier status plus fetal risk for recessive conditions, and avoid losing patients when partner testing never happens.

• Natera Panorama, Myriad Prequel, and Quest QNatal are positioned around chromosome abnormalities, including common aneuploidies and in some cases microdeletions. That makes them strong at the biggest NIPT use case, but it leaves single gene recessive disease risk as a separate workflow rather than the core product.
  2 natera 3 myriad 4 questwomenshealth
• UNITY was built around the gap in carrier screening follow through. Traditional screening often starts with the mother, then requires paternal testing to estimate fetal risk if she is a carrier. BillionToOne instead reads maternal carrier status and fetal cfDNA from the same maternal sample, which is especially useful when the father is unavailable or testing would delay care.
  1 billiontoone 5 sacra 6 sacra
• That product difference matters commercially because BillionToOne sells into OB GYNs, hospitals, and fertility clinics where fewer steps means fewer dropped cases. The company reached about 15% U.S. prenatal testing share and 500,000 total prenatal tests processed, showing that a simpler ordering path can win share even against a market led by Natera at roughly 60%.
  5 sacra 6 sacra

The next phase is a shift from being a niche add on to becoming a standard prenatal order set. As UNITY expands its fetal risk panel and keeps fitting inside existing OB workflows, BillionToOne is positioned to pull more screening volume away from chromosome only tests and turn single gene risk assessment into a routine first line prenatal screen.